TABLE 2.
Pathway enrichment of luteolin pre-treated group.
| Pathway enrichment | |||||
|---|---|---|---|---|---|
| NO | Pathway ID | Pathway | Count | % | p-value |
| 1 | rno01100 | Metabolic pathways | 62 | 0.086,741,189 | 9.24344E-06 |
| 2 | rno00190 | Oxidative phosphorylation | 16 | 0.022,384,823 | 1.03828E-05 |
| 3 | rno05012 | Parkinson’s disease | 16 | 0.022,384,823 | 1.99834E-05 |
| 4 | rno05010 | Alzheimer’s disease | 16 | 0.022,384,823 | 0.00016011 |
| 5 | rno01130 | Biosynthesis of antibiotics | 17 | 0.023,783,875 | 0.000387,545 |
| 6 | rno05016 | Huntington’s disease | 15 | 0.020,985,772 | 0.001,562,905 |
| 7 | rno04932 | Non-alcoholic fatty liver disease (NAFLD) | 13 | 0.018,187,669 | 0.001,843,786 |
| 8 | rno03320 | PPAR signaling pathway | 7 | 0.00979,336 | 0.02,007,818 |
| 9 | rno00480 | Glutathione metabolism | 6 | 0.008,394,309 | 0.022,249,139 |
| 10 | rno00270 | Cysteine and methionine metabolism | 5 | 0.006,995,257 | 0.024,500,584 |
| 11 | rno00900 | Terpenoid backbone biosynthesis | 4 | 0.005,596,206 | 0.025,077,535 |
| 12 | rno04152 | AMPK signaling pathway | 9 | 0.012,591,463 | 0.026,348,516 |
| 13 | rno04540 | Gap junction | 7 | 0.00979,336 | 0.035,775,325 |
| 14 | rno03050 | Proteasome | 5 | 0.006,995,257 | 0.041,183,838 |
| 15 | rno04115 | p53 signaling pathway | 6 | 0.008,394,309 | 0.045,094,341 |
| 16 | rno05206 | MicroRNAs in cancer | 9 | 0.012,591,463 | 0.046,195,794 |